Search for Clinical Trial Results

Idiopathic Pulmonary Fibrosis - 27 Studies Found
Status | Study |
Completed |
Study Name: Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2010-09-30 Interventions:
|
Recruiting |
Study Name: Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2015-12-13 |
Completed |
Study Name: Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2003-12-18 Interventions: Drug: FG-3019 |
Completed |
Study Name: Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2003-10-23 Interventions:
|
Recruiting |
Study Name: Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2016-04-01 Interventions:
|
RECRUITING |
Study Name: The Effect of N115 on Coughing in IPF Patients Condition: Idiopathic Pulmonary Fibrosis Date: 2025-02-06 Interventions: The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7. |
RECRUITING |
Study Name: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2025-02-06 Interventions: Specified dose on specified days |
RECRUITING |
Study Name: Atezolizumab for Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2025-02-06 Interventions: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks |
RECRUITING |
Study Name: Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2025-02-06 Interventions: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death. |
RECRUITING |
Study Name: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis (IPF) Date: 2025-02-06 Interventions: Pharmaceutical formulation: CapsulesMode of Administration: Oral |